Approaches to Bridging Therapy During the CAR T Manufacturing Process
Panelists discuss how bridging therapy during the CAR T manufacturing waiting period requires careful patient-specific decisions about whether to use chemotherapy, targeted agents, or observation alone, based on disease aggressiveness, patient condition, and expected manufacturing timeframes.
EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM
EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?
EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria
EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process
EP: 5.Reviewing CAR T Mechanism & Treatment Process
EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process
Video content above is prompted by the following:
- Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
